MMC boost for trabeculectomy

Article

Perioperative use of mitomycin-C (MMC) improves the long-term outcomes of trabeculectomy as a treatment for primary open-angle glaucoma (POAG), according to a study published online ahead of print by the British Journal of Ophthalmology.

Perioperative use of mitomycin-C (MMC) improves the long-term outcomes of trabeculectomy as a treatment for primary open-angle glaucoma (POAG), according to a study published online ahead of print by the British Journal of Ophthalmology.

Antonio Longo of the Eye Clinic at the University of Catania, Italy and colleagues conducted a retrospective chart review of subjects suffering from POAG (n=114) who were involved in a randomized clinical trial (held 1995–1998) in which they underwent trabeculectomy in one eye and received a intraoperative dose of either MMC 0.2 mg/ml (n=67) or balanced saline solution (BSS; n=47).

Eyes treated with MMC had a mean intraocular pressure (IOP) value of 13.33±3.35 mmHg, compared with a mean IOP of 14.72±2.19 mmHg in the BSS group. In the MMC-treated group, 73.1% of subjects had IOP ≤18 mmHg and 56.7% of subjects had IOP ≥14 mmHg; in the BSS group, this was 51.1% and 31.9% of patients, respectively. Only 9% of MMC-treated patients required further glaucoma surgery, compared with 25.5% of BSS-treated patients. The damage to the visual field progressed in 21.1% of MMC-treated patients, compared with 48.6% of BSS-treated patients. In terms of the incidence of complications, there was no difference seen between groups, although one eye treated with MMC went on to develop blebitis.

Thus the team concluded that using MMC during trabeculectomy did not increase the rate of complications. It did, however, improve IOP outcomes and decrease the risk of both further visual field damage and repeated surgical interventions.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.